Purpura clinical trials
The registry lists 45 studies for Purpura across more than 10 countries. 4 are recruiting or about to start. 22 of them are mainly about Purpura (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its 4 narrower conditions too, such as Purpura, Thrombocytopenic, Idiopathic: 633 studies, 188 open.
Get an email when these change. Save the Purpura studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (12) · Shandong University (7) · Novartis Pharmaceuticals (3) · Takeda (2) · AO GENERIUM (2) · Universidad Autonoma de San Luis Potosí (1) · Merck Sharp & Dohme LLC (1) · CASI Pharmaceuticals, Inc. (1)
What is being tested here
Drugs under test in Purpura studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Oct 2027Finerenone Therapy for Pediatric HSPN With Mild Proteinuria · Capital Institute of Pediatrics, China
Who these studies take
Of the 4 Purpura studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 3 (75%) | 3 (75%) |
| 40 | 3 (75%) | 3 (75%) |
| 50 | 3 (75%) | 3 (75%) |
| 65 | 3 (75%) | 3 (75%) |
| 75 | 2 (50%) | 2 (50%) |
| 85 | 2 (50%) | 2 (50%) |
Across all 45 studies, recruiting or not: 51% stop at 75 or younger and 24% at 65; 27% take children; 0% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 45 of 45. search them.
- A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06722235Phase 318 countries
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06948318Phase 315 countries
- Finerenone Therapy for Pediatric HSPN With Mild ProteinuriaRecruitingNCT07315191Phase 41 country
- A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaRecruitingNCT07017725Phase 1/21 country
- Evaluation of Tretinoin Cream on the Integrity of Aged Forearm SkinCompletedNCT07084116Phase 2/31 country
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 15 countries
- S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary AmyloidosisCompletedNCT03499808Phase 21 country
- Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.CompletedNCT06288932Phase 31 country
- Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP PatientsCompletedNCT05492409Phase 31 country
- Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITPCompletedNCT05220878Phase 31 country
- Prevalence and Comorbidities of Dermatoporosis: a French Prospective Observational Study in General Medicine ConsultationCompletedNCT056999801 country
- Investigation on a Dynamic Cohort of Italian Patients With Active ITPStatus unknownNCT034650201 country
- Factors Associated With DermatoporosisCompletedNCT050376041 country
- Microneedling for DermatoporosisStatus unknownNCT04912219Not applicable
- Drug Use Investigation for REVOLADE (ITP)CompletedNCT01416311
- Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang GranulesStatus unknownNCT04623866Early Phase 11 country
- ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITPCompletedNCT019716842 countries
- Eltrombopag Phase III Study In Chinese Chronic ITP PatientsCompletedNCT01762761Phase 31 country
- Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and HandsCompletedNCT01910831Phase 41 country
- Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)CompletedNCT01963260Phase 1
- Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00908037Phase 26 countries
- Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITPStatus unknownNCT03252457Phase 31 country
- Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep TreatmentStatus unknownNCT03591471Phase 1/21 country
- Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of EltrombopagCompletedNCT00688272Phase 11 country
- Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food EffectCompletedNCT01072162Phase 11 country
- Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic ImpairmentCompletedNCT00359463Phase 13 countries
- Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal ImpairmentCompletedNCT00442871Phase 11 country
- The Study of Different Dose Rituximab in the Treatment of ITPCompletedNCT03258866Phase 41 country
- Tacrolimus in Children With Henoch-Schönlein Purpura NephritisCompletedNCT03222687Phase 4
- RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With EltrombopagCompletedNCT00370331Phase 325 countries
- EXTEND (Eltrombopag Extended Dosing Study)CompletedNCT00351468Phase 331 countries
- LENS - Long-term Eltrombopag Observational StudyCompletedNCT0064392921 countries
- Promacta Pregnancy RegistryCompletedNCT01064336
- rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITPCompletedNCT01525836Phase 31 country
- Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT01734057Phase 31 country
- All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT01882127Phase 31 country
- Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)CompletedNCT01506414Phase 31 country
- rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITPCompletedNCT01734044Phase 31 country
- Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged SkinCompletedNCT00272610Phase 21 country
- A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT01098487Phase 411 countries
- A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.WithdrawnNCT01440361Phase 2
- Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)CompletedNCT00424177Phase 22 countries
- SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00102739Phase 213 countries
- A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile PurpuraStatus unknownNCT01485367Phase 21 country
- A Novel Oral Natural Extract for the Treatment of Senile PurpuraStatus unknownNCT01183910Not applicable1 country